Background
==========

Soft tissue sarcomas (STSs) are relatively rare but aggressive tumors that account for approximately 0.7% of all cancers and 0.8% of cancer mortality [@B1]. STSs are biologically heterogeneous and due to diverse histology, are classified into over 70 subtypes, with every type exhibiting differences in terms of characteristics, treatment and prognosis [@B2]. Despite advances in multidisciplinary treatment, the probability of local recurrence and metastasis remains high for STS patients, particularly for those with high-grade tumors owing to the rapid clinical progression of the disease [@B3]. The 5-year relative survival rate for STS is approximately 65% [@B4], yet up to 50% of patients will develop metastases and die from their disease [@B5]. Therefore, it is important to identify easily obtainable and economically feasible clinical tools that can help guide treatment options and enhance the capability of risk stratification.

Growing evidence demonstrates a critical role of the systemic inflammatory response (SIR) in the development and progression of cancer as well as the response to therapy [@B6], [@B7]. Accordingly, several inflammation-based prognostic markers, such as C-reactive protein (CRP) [@B8], the Glasgow Prognostic Score (GPS) [@B9], and the high-sensitivity modified Glasgow prognostic score (Hs-mGPS) [@B10], have been proposed as independent predictors of survival in various types of malignancies, including STS [@B11]. In addition, as important components of SIR, neutrophils, lymphocytes, and platelets are recognized as participating in the proliferation and migration of tumor cells [@B12]-[@B15]. Recently, two studies indicated that the neutrophil-to-lymphocyte ratio (NLR), a representative index derived from inflammatory cells, can serve as a prognostic factor in STS [@B16], [@B17]. Similarly, the platelet-to-lymphocyte ratio (PLR), another SIR indicator based on routine blood analysis, has prognostic value for STS [@B18]. However, the combined use of these two indices for STS prognosis has not yet been assessed.

Therefore, we incorporated both ratios into a novel measure, the CNP (the combination of NLR and PLR) scoring system and evaluated its prognostic value in patients with operable STS. We also assessed whether CNP can provide additional information compared with NLR or PLR alone.

Methods
=======

Patients
--------

All STS patients who underwent extensive and radical resection at Sun Yat-sen University Cancer Center (SYSUCC) from October 1999 to August 2013 were carefully reviewed retrospectively. The inclusion criteria were (1) histologically confirmed STS; (2) surviving at least 30 days postoperatively; (3) without any chemotherapy and/or radiotherapy before serum collection; and (4) adequate and available medical record and following-up data. Patients were excluded if they presented with an acute infection or chronic inflammatory disease, malignancy or any other known autoimmune disorder. Patients with recurrence at presentation or those who were referred for additional resection after previously undergoing unplanned excision were excluded. Finally, a total of 310 patients were included in this study.

Clinical Data Collection
------------------------

Laboratory data, including quantification of neutrophils, lymphocytes, and platelets, and other basic hematological parameters, were obtained one week prior to surgery. In cases in which patients received more than one serum test, we utilized the most recent test. Clinical data, such as age at diagnosis, gender and histopathological diagnosis, were extracted retrospectively from the medical records. Stage was classified according to the American Joint Committee on Cancer (AJCC) 7th Edition [@B19], and tumors were graded according to the French Federation of Cancer Centers Sarcoma Group (FNCLCC) grading system [@B20]. NLR was defined as the absolute neutrophil count divided by the absolute lymphocyte count. PLR was defined as the absolute platelet count divided by the absolute lymphocyte count. Based on receiver operating characteristic (ROC) curves analyses, the optimal cut-off values of NLR and PLR were 2.51 and 191.1, respectively. We combined the two indicators to define the CNP score as follows: patients with both an elevated NLR (\>2.51) and PLR (\>191.1) were allocated a score of 2; patients with only one elevated value were allocated a CNP score of 1; patients without abnormalities were allocated a score of 0. Scores of 2, 1 and 0 were classified as "high risk," "intermediate risk" and "low risk," respectively.

The authenticity of this article was validated by uploading the key raw data to the Research Data Deposit public platform ([www.researchdata.org.cn](http://www.researchdata.org.cn)) with the approval RDD number of RDDA2017000452.

Patient Follow-up
-----------------

Patients were followed-up at our independent follow-up program department every 3 to 6 months for the first 2 years after resection and annually thereafter. Follow-up data were available from patient files or by telephone interview with the patients or guardians. The primary end-point of the study was overall survival (OS), which was defined as the time in months between the operation and death from any cause or to the last date of follow-up (May 01, 2017). The secondary end-point was disease-free survival (DFS), which was determined from the date of resection to the date of tumor recurrence or distant metastasis.

Statistical Analysis
--------------------

Data are presented as a number (%). Comparisons between the three CNP groups were performed using the chi-square (χ2) test. The Spearman correlation test was conducted to evaluate relationships between NLR and PLR, and NRP, PLR and OS. The optimal cut-off points for NLR and PLR were determined by ROC analysis, and areas under the curve (AUCs) were calculated. The overall cumulative probability of survival was calculated using the Kaplan-Meier method, and differences in survival rates were determined using the log-rank test. Prognostic variables associated with OS and DFS that were significant in univariate analyses were selected for multivariate Cox proportional hazards regression analysis using the forward stepwise method. Hazard ratios (HR) estimated from the Cox analysis are reported as relative risks with corresponding 95% confidence intervals (CIs). P values were derived from two-tailed tests. A p-value less than 0.05 was considered statistically significant. All analyses were performed using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA.).

Results
=======

Patient and Tumor Characteristics
---------------------------------

Among the 310 patients with STS, 136 (43.9%) were women and 174 (56.1%) men. The median age was 39 years, with a range of 5-78 years. At a median follow-up period of 88 months (interquartile range, 47.5-119.25 months), 112 (36.1%) patients had local relapse, 61 (19.7%) developed disease recurrence, and 98 (31.6%) died.

The primary tumor sites were located in the upper extremities (n=35), lower extremities (n=82), thorax/trunk (n=91), intra-abdominal (n=48), and head/neck (n=48). The mean tumor size at diagnosis was 6.6 cm (1 to 28). The depth of the tumor was superficial in 127 patients and deep in 183 patients. Tumor pathological subtypes included so-called malignant fibrous histiocytoma (MFH) in 78 patients (25.2%), fibrosarcoma in 59 (19.0%), synovial sarcoma in 40 (12.9%), and liposarcoma in 37 (11.9%). A total of 82 patients had grade one sarcoma, 119 had grade two, and 80 had grade three. The majority of patients had stage I or II disease (224/310, 72.3%); 62 (20.0%) had stage III or stage IV.

A total of 202 patients (65.2%) had a score of 0; 75 (24.2%) had a score of 1, and 33 (10.6%) had a score of 2. Adjuvant treatments, including chemotherapy (mostly doxorubicin-based combination chemotherapy) and radiotherapy, were planned according to the tumor stage, doctor\'s selection and patient\'s desire. The baseline characteristics of the 310 patients are presented in Table [1](#T1){ref-type="table"} and Table [S1](#SM0){ref-type="supplementary-material"}.

Relationships between NLR and PLR, and NLR, PLR and OS
------------------------------------------------------

We examined the association between NLR, PLR, and NLR, PLR and OS. We found a significant negative correlation between serum NLR and OS (r=-0.175, P=0.002) (Fig. [S1](#SM0){ref-type="supplementary-material"}a), and between serum PLR and OS (r=-0.180, P=0.001) (Fig. [S1](#SM0){ref-type="supplementary-material"}b). In addition, a positive association between NLR and PLR (r=0.606, P=0.000) was observed (Fig. [S1](#SM0){ref-type="supplementary-material"}c).

Determination of Optimal Cut-off Values
---------------------------------------

ROC analysis and AUC calculations (Table [S2](#SM0){ref-type="supplementary-material"}) revealed that an NLR value of 2.51 should be considered the recommended cut-off value because it was closest to the maximum joint sensitivity (0.459) and specificity (0.764) in predicting OS (AUC: 0.608, 95% CI:0.537-0.678, P=0.002). Similarly, the optimal cutoff value for PLR was 191.1 (AUC: 0.614, 95% CI: 0.543-0.686, P=0.001), with a sensitivity and specificity of 0.306 and 0.929, respectively. The AUC for CNP was 0.644 (95% CI: 0.574-0.713, P=0.000).

Correlation between CNP and Clinicopathological Characteristics
---------------------------------------------------------------

Table [1](#T1){ref-type="table"} presents the distribution of the clinical background characteristics of the patients in the three CNP groups. The data showed elevated CNP to be significantly associated with older age (P=0.034), larger tumor size (P=0.025), deeper tumor location (P=0.044), higher tumor grade (P=0.028) and more advanced AJCC stage (P=0.005). No significant differences in gender or tumor site were identified among the three groups (P=0.244, P=0.132 respectively).

Survival Analysis
-----------------

Kaplan-Meier analysis and the log-rank test showed that high-risk patients had a poorer prognosis than those with intermediate or low risk. An elevated CNP score was significantly associated with shorter OS (P=0.000) and DFS (P=0.000) (Fig. [1](#F1){ref-type="fig"}). The recurrence and death rates of patients in CNP groups 0, 1 and 2 differed significantly: 30.20, 37.33 and 69.70%, 23.80, 33.30 and 75.80%, respectively (P=0.000; Fig. [2](#F2){ref-type="fig"}).

In univariate analyses of OS and DFS, NLR, PLR and CNP were all found to be prognostic factors. Other identified prognostic factors included tumor size, tumor depth, tumor grade and AJCC stage (Table [2](#T2){ref-type="table"}).

Multivariate analyses using the variables selected from univariate analysis as covariates revealed that preoperative CNP was also an independent prognostic factor for OS and DFS (P*=*0.001 and P*=*0.000, respectively). The risk of succumbing to STS for patients with a CNP=2 was \>3 times higher than that for patients with CNP=0 (OR=3.425; P=0.000; 95% CI, 2.112-5.640). Tumor depth and tumor grade were also identified as independent predictors of DFS and OS, whereas NLR and PLR were not statistically significant (Table [3](#T3){ref-type="table"}).

In individual subgroup analysis, we found that OS and DFS were better predictors in patients with intermediate or low risk in the G1/G2 subgroup (P=0.000, P=0.001), G3 subgroup (P=0.003, P=0.009) and stage I/II (P=0.000, P=0.000) and III/IV (P=0.000, P=0.014) subgroups (Fig. [3](#F3){ref-type="fig"}).

Discussion
==========

Despite recent progress in the identification of molecular and genetic alterations in STS [@B2], [@B21], [@B22], routine prognostic risk assessment of STS patients still relies on the traditional model. These traditional prognostic factors have yet to be improved by the incorporation of novel biomarkers, which might be beneficial for individualized treatment. In the present study, we investigated the prognostic value of NLR and PLR as well as CNP, a novel incorporated prognostic system, for 310 STS patients undergoing resection. To the best of our knowledge, this is the first study to show that CNP is associated with tumor progression and can be considered an independent marker of prognosis for patients with STS.

Cumulative evidence has proven that inflammation is a hallmark of cancer. Indeed, cancer-related inflammation can suppress host antitumor immunity and affect tumor response to therapy [@B14], [@B23]. Moreover, the association between SIR and poor prognosis has been reported for many types of cancer, including STS [@B11], [@B24]. Nonetheless, the mechanism by which inflammatory cells influence cancer is multifaceted and remains speculative. For example, tumor cells produce various cytokines, such as granulocyte colony-stimulating factor, tumor necrosis factor (TNF), interleukin (IL)-1, -6, and -8 and vascular endothelial growth factor (VEGF), which activate and recruit neutrophils to the tumor stroma to promote growth [@B25]. Neutrophils, in turn, release several mediators to provide a stimulating microenvironment that allows for more aggressive tumor behavior by sustaining cell proliferation and facilitating genomic instability [@B13], [@B15]. Furthermore, neutrophils interfere with T lymphocyte function and promote mutagenesis, rendering some individuals more susceptible to carcinogenesis and future cancer progression [@B26]. Lymphocytes have a key role in tumor defense by inducing cytotoxic cell death and inhibiting tumor cell proliferation and migration [@B27], and it has been reported that high lymphocytic infiltration into the tumor stroma is associated with better survival and a superior response to systemic therapy [@B28]. Thus, NLR, a measure of the relative difference between neutrophil and lymphocyte counts, can serve as a prognostic factor for tumor progression and outcome [@B29], [@B30].

In addition, the hypercoagulable state has also been correlated with malignancy, accounting for a significant percentage of mortality and morbidity in cancer patients [@B31]. Among coagulation factors, platelets play an essential role in both inflammation and cancer progression by decreasing apoptosis and increasing angiogenesis, thereby promoting the metastatic potential of tumor cells [@B32]. In turn, tumor cells release procoagulant molecules to activate platelet activity and induce platelet aggregation, which has been proposed to trigger the development of cancer-associated thrombosis [@B33]. Numerous studies have reported that a high PLR is a negative predictor of prognosis in solid tumors [@B18], [@B30].

Regardless, in certain cases, NLR and PLR may not function as tumor-specific markers because hormonotherapy and other inflammatory conditions can be confounding factors. Some authors have suggested that NLR or PLR should be assessed together with other inflammatory markers [@B34]. In light of the above evidence, we attempted to create a new scoring system by combining both NLR and PLR, termed CNP, which is theoretically more convincing and reflects a mixed prognostic value for predicting survival.

In our study of 310 STS patients, we identified significant relationships between NLR and PLR and between NLR, PLR and OS; these results suggest that these parameters can serve as biological markers for prognostic estimates. In addition, according to ROC curve analysis, the AUC value of CNP exceeded those of NLR and PLR, for a more convincing conclusion that CNP exhibits comparable prognostic ability that is even stronger than NLR or PLR alone.

Furthermore, the prognosis of patients worsened as the CNP score increased from 0 to 1 to 2, which is similar to findings reported in patients with hepatocellular carcinoma [@B35] and gastric cancer [@B36]. More importantly, we found that patients who had a higher CNP score were more likely to be older in age and have a larger tumor size, a deeper tumor location, a higher tumor grade and a more advanced AJCC stage compared with those with a low CNP score. These findings show that CNP may indicate a more aggressive tumor in STS patients. Cummings et al. [@B37] also found that an elevated CNP was associated with advanced stage, high tumor burden and metastatic potential in endometrial cancer, thus demonstrating that high CNP significantly parallels tumor progression. Their conclusion was consistent with the findings of our study.

Univariate analysis revealed that all inflammation-based prognostic scores have statistical significance regarding OS and DFS. However, after excluding confounding factors using a Cox regression model of multivariate analysis, we found that only CNP, and not NLR or PLR, was independently associated with OS and DFS. Kaplan-Meier analysis and the log-rank test showed that CNP was able to divide patients into three independent groups. These findings suggest that CNP has a substantial effect and is superior to NLR or PLR as a predictive factor in patients with STS. Although no studies have evaluated simultaneous measurement of these markers in patients with STS, Feng*et al*. concluded that the combination of NLR and PLR is a significant predictor of OS, with greater value than when used alone in patients with resected esophageal squamous cell carcinoma [@B38]. Goh *et al*. produced similar findings in gastrointestinal stromal tumors [@B34]. Further subgroup analysis also showed a high CNP to be associated with decreased OS and DFS in G1-2, G3, stage I-II and III-IV subgroups. CNP has strong discriminatory power in STS patients with different grades and stages.

Over the last decade, there have been massive efforts to identify clinical biomarkers for predicting outcomes in tumor patients, though expense and technological limitations have precluded their use. Blood-based biomarkers are now recognized to be attractive practical tools, as peripheral blood is easily accessible, routinely tested and relatively noninvasive. Therefore, a blood count-derived measure, CNP has the advantage of being easily measurable, cost-efficient and highly repeatable in clinical practice. Moreover, CNP may constitute a new and valuable tool for custom surveillance schedules and individualized therapeutic strategies for patients of different risk subgroups. Patients with a high preoperative CNP value may require more intense therapy and more frequent follow-up.

As with all studies, this work has several limitations. First, the study is limited by its retrospective nature and the mixture of various histological types of STS. Second, the sample size collected from a single center was relatively small, and thus it is difficult to perform further verification analysis by separating patients into training and validation cohorts. In addition, information on operational approaches and adjuvant therapies was incomplete, which may have influenced our analysis. Another limitation is the fact that we did not routinely measure and analyze other systemic inflammatory serum markers, such as CRP or Hs-mGPS. Consequently, future studies, particularly prospective multicenter trials with a large cohort, are required to confirm our results and to assess the validity of the prognostic predictors.

Conclusions
===========

In conclusion, our study provides the first evidence that CNP, a novel and economical inflammation-based prognostic score, is associated with tumor progression and can be considered an independent prognostic factor for predicting OS and DFS in STS patients. Moreover, compared to the established prognostic indices of PLR and NLR, CNP displayed superior prognostic ability in our study population. We recommend the routine measurement of this marker in clinical practice. Nonetheless, larger prospective studies are warranted to confirm these preliminary results and to investigate the underlying mechanisms.
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![Kaplan-Meier curves showing overall survival and disease-free survival according to CNP in 310 STS patients. Patients were stratified according to the grade and AJCC stage.**(a)** Kaplan-Meier analysis of overall survival in G1-2 subgroup. **(b)** Kaplan-Meier analysis of overall survival in G3 subgroup. **(c)** Kaplan-Meier analysis of overall survival in I+II subgroup. **(d)** Kaplan-Meier analysis of overall survival in III+IV subgroup. **(e)** Kaplan-Meier analysis of disease-free survival in G1-2 subgroup. **(f)** Kaplan-Meier analysis of disease-free survival in G3 subgroup. **(g)** Kaplan-Meier analysis of disease-free survival in I+II subgroup. **(h)** Kaplan-Meier analysis of disease-free survival in III+IV subgroup.](jcav09p2132g003){#F3}

###### 

The relationships between CNP and clinicopathological characteristics

  Variables            All patients   Score 0 (n=202)   Score 1(n=75)   Score 2(n=33)   *p*-value
  -------------------- -------------- ----------------- --------------- --------------- -----------
  Gender                                                                                
  Male                 174(56.1)      117(57.9)         43(57.3)        14(42.4)        0.244
  Female               136(43.9)      85(42.1)          32(42.7)        19(57.6)        
  Age (years)                                                                           
  \<50                 208(67.1)      145(71.8)         46(61.3)        17(51.5)        0.034
  ≥50                  102(32.9)      57(28.2)          29(38.7)        16(48.5)        
  Performance status                                                                    0.001
  0                    237(76.5)      168(83.2)         52(69.3)        17(51.5)        
  ≥1                   73(23.5)       34(16.8)          23(30.7)        16(45.5)        
  Tumor size (cm)                                                                       0.025
  \<5                  143(46.1)      104(51.5)         29( 38.7)       10( 30.3)       
  ≥5                   167(53.9)      98(48.5)          46( 61.3)       23( 69.7)       
  Tumor site                                                                            0.132
  Upper extremity      35(11.3)       25(12.2)          5(6.7)          5(16.7)         
  Lower extremity      82(26.5)       62(30.2)          14(18.7)        6(20)           
  Thoracic/trunk       91(29.4)       62(30.2)          22(29.3)        7(23.3)         
  Intra-abdominal      48(15.5)       28(13.7)          16(21.3)        4(13.3)         
  Head/neck            48(15.5)       24(11.7)          16(21.3)        8(26.7)         
  Others               6(1.9)         4(2.0)            2(2.7)          0(0.0)          
  Tumor depth                                                                           0.044
  Superficial          127(41.0)      90(45.0)          29(38.6)        8(22.9)         
  Deep                 183(59.0)      110(55.0)         46(61.4)        27(77.1)        
  Tumor grade                                                                           0.028
  G1                   82(26.4)       64(31.7)          16(21.3)        2(6.1)          
  G2                   119(38.4)      77(38.1)          29(38.7)        13(39.4)        
  G3                   80(25.8)       43(21.3)          23(30.7)        14(42.4)        
  Missing              29(9.4)        18(8.9)           7(9.3)          4(12.1)         
  AJCC stage                                                                            0.005
  IA+IB                83(26.8)       65(32.2)          16(21.3)        2(6.1)          
  IIA+IIB              141(45.5)      92(45.5)          31(41.3)        18(54.5)        
  III+IV               62(20.0)       29(14.4)          23(30.7)        10(30.3)        
  Unknown              24(7.1)        16(7.9)           5(6.7)          3(9.1)          
  End-point                                                                             0.000
  Alive                212(68.4)      154(76.2)         50(66.7)        8(24.2)         
  Dead                 98(31.6)       48(23.8)          25(33.3)        25(75.8)        
  Recurrence                                                                            0.000
  YES                  112(36.1)      61(30.2)          28(37.3)        23(69.7)        
  NO                   198(63.9)      141(69.8)         47(62.7)        10(30.3)        
  Metastasis                                                                            0.001
  YES                  61(19.7)       31(15.3)          16(21.3)        14(42.4)        
  NO                   249(80.3)      171(84.7)         59(78.7)        19(57.6)        

###### 

Univariate analyses of DFS and OS in STS patients

                    Disease-free survival   Overall survival                          
  ----------------- ----------------------- ------------------ ---------------------- -------
  Sex                                       0.934                                     0.190
  Male              1.000                                      1.000                  
  Female            1.014(0.730-1.09)                          1.304(0.877-1.937)     
  Age (years)                               0.011                                     0.395
  \<50              1.000                                      1.000                  
  ≥50               1.538(1.103-2.145)                         1.195(0.793-1.802)     
  Tumor size (cm)                           0.000                                     0.014
  \<5               1.000                                      1.000                  
  ≥5                2.181(1.537-3.093)                         1.676(1.109-2.535)     
  Tumor depth                               0.000                                     0.000
  Superficial       1.000                                      1.000                  
  Deep              3.006(2.043-4.422)                         3.174(1.942-5.190)     
  Tumor grade                               0.000                                     0.000
  G1                1.000                                      1.000                  
  G2                2.268(1.340-3.837)                         4.339(1.821-10.336)    
  G3                5.300(3.132-8.971)                         10.918(4.647-25.652)   
  AJCC stage                                0.000                                     
  IA+IB             1.000                                      1.000                  0.000
  IIA+IIB           2.294(1.402-3.751)                         4.571(2.065-10.115)    
  III+IV            5.089(3.014-8.590)                         9.540(4.224-21.544)    
  NLR                                       0.001                                     0.000
  \<2.51            1.000                                      1.000                  
  ≥2.51             1.778(1.271-2.487)                         2.229(1.497-3.318)     
  PLR                                       0.000                                     0.000
  \<191.1           1(referent)                                1.000                  
  ≥191.1            2.498(1.688-3.698)                         3.585(2.327-5.522)     
  CNP                                       0.000                                     0.000
  0                 1(referent)                                1.000                  
  1                 1.363(0.924-2.011)                         1.570(0.968-2.547)     
  2                 3.333(2.129-5.218)                         4.653(2.863-7.566)     

DFS, disease-free survival; OS, overall survival; STS, Soft tissue sarcomas; HR, hazard ratio; CI, confidence interval; G, grade; AJCC, American Joint Committee on Cancer; NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio; CNP, the combination of neutrophil lymphocyte ratio and platelet lymphocyte ratio.

###### 

Multivariate analyses of DFS and OS in STS patients

                Disease-free survival   Overall survival                         
  ------------- ----------------------- ------------------ --------------------- -------
  Age (years)                           0.017                                    
  \<50          1.000                                                            
  ≥50           1.513(1.077-2.126)      0.017                                    
  Tumor depth                           0.000                                    0.001
  Superficial   1.000                                      1.000                 
  Deep          2.378(1.606-3.521)      0.000              2.241(1.363-3.685)    
  Tumor grade                           0.000                                    0.000
  G1            1.000                                      1.000                 
  G2            1.717(0.999-2.931)      0.050              2.931(1.213-7.079)    0.017
  G3            4.085(2.371-7.037)      0.000              7.165(3.006-17.976)   0.000
  CNP                                   0.001                                    0.000
  0             1.000                                      1.000                 
  1             1.238(0.837-1.830)      0.285              1.396(0.858-2.272)    0.179
  2             2.427(1.533-3.841)      0.000              3.452(2.112-5.640)    0.000

DFS, disease-free survival; OS, overall survival; STS, Soft tissue sarcomas; HR, hazard ratio; CI, confidence interval; G, grade; CNP, the combination of neutrophil lymphocyte ratio and platelet lymphocyte ratio.
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